Today's Date: September 25, 2023
Statement by the Prime Minister on Yom Kippur   •   Disappointment and Hope after U.N. General Assembly Wraps, says AHF   •   France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival   •   Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery   •   Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits   •   65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders   • collaborates with   •   PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE   •   No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty   •   2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS   •   Statement by Minister Khera on Yom Kippur   •   A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser   •   Wondershare FamiSafe 7.0 safeguarding Children with AI   •   Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans   •   THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON   •   Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo   •   Guidewire Optimistic About New Direction of California Insurance   •   2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop   •   Intel Editorial: Intel Addresses Semiconductor Workforce Shortage   •   Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize
Bookmark and Share

Seneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors

PHILADELPHIA , June 05 /Businesswire/ - Seneca Therapeutics, Inc. (STI), today announced the appointment of Cuong Do, MBA to its Board of Directors.

"Cuong has successfully financed and led several life science biotech companies across a range of therapeutic areas, and we are extremely excited to welcome him to our Board," said James Hussey, Chief Executive Officer of Seneca Therapeutics, Inc. "Cuong’s extensive executive leadership experience, together with his strategic expertise, will help guide us as we advance our neuroendocrine neoplasm (NEN) cancer programs towards late-stage trials. He will also work to deepen our relationships with leading biopharmaceutical companies. His background is extremely complementary with those of our leadership team and is strategically aligned with the long-term R&D goals of the company. I look forward to working together."

Mr. Do added, "The opportunity to join Seneca Therapeutics at this crucial stage in the Company's evolution is compelling. Clinical data has already demonstrated SVV-001’s ability to provide significant patient benefit in many cancer indications. SVV-001’s potential to synergize with checkpoint inhibition and drive objective responses in NEN is especially exciting.”

“Seneca Therapeutics’ upcoming clinical trial in patients with NEN cancer will provide valuable opportunities to accelerate SVV-001’s path towards registration in these indications. I am excited to welcome Cuong’s insights to company management and the Board as we work towards these potential catalysts and prepare for anticipated growth," said Chief Scientific Officer and President of Seneca Therapeutics, Paul Hallenbeck, PhD.

Mr. Do joins STI’s Board with over two decades of experience in the pharmaceutical and biotechnology industries. He is currently the Chief Executive Officer (CEO) of BioVie where he leads a team focused on the development of treatments for Alzheimer’s Disease. Prior to his appointment with BioVie, Mr. Do was President of Samsung Electronics Co., Ltd. Global Strategy Group where he helped set the strategic direction for Samsung’s diverse business portfolio. He was previously the Chief Strategy Officer for Merck and Company, a leading US pharmaceuticals company. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years helping to build the health care, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.

About Seneca Therapeutics

Seneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.

Forward-Looking Statements

This press release contains “forward-looking statements” concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.

STORY TAGS: Personnel, Pennsylvania, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News